Siemens Healthcare Diagnostics, a global leader in clinical diagnostics, provides healthcare professionals in hospital, reference, and physician office laboratories and point-of-care settings with the vital information required to accurately diagnose, treat, and monitor patients. Our innovative portfolio of performance-driven solutions and personalized customer care combine to streamline workflow, enhance operational efficiency, and support improved patient outcomes.
MicroScan is a trademark of Siemens Healthcare Diagnostics Inc.
Not available for sale in the U.S.
Product availability may vary from country to country and is subject to varying regulatory requirements. Please contact your local representative for availability.
Order No. A91DX-MM-131348-GC1-4A00 11-2013 | All rights reserved 2013 Siemens Healthcare Diagnostics Inc.
Global Siemens Headquarters Siemens AG Wittelsbacherplatz 2 80333 Muenchen Germany
Global Siemens Healthcare Headquarters Siemens AG Healthcare Sector Henkestrasse 127 91052 Erlangen Telephone: + 49 9131 84-0 Germany
www.siemens.com/healthcare
www.siemens.com/diagnostics
Your First Choice in Resistance DetectionMicroScan Gram Positive Conventional Panels
www.siemens.com/microbiology
Answers for life.
For more than 30 years, MicroScan Systems have been exclusively focused on ID/AST testing, offering unmatched experience, expertise, and technical support to help guide physicians and improve patient care. MicroScan Dried Overnight Gram Positive Panels from Siemens now continue a tradition of quality and innovation. They are designed to help keep your laboratory staff at the forefront of identification and susceptibility testing and are compatible with all MicroScan instruments. Provide clinically relevant
identification from an extensive database of gram-positive microorganisms
Detect inducible clindamycin resistance on all Staphylococcus species (98.7% category agreement to reference method)
Enhance accuracy of MRSA detection using integrated cefoxitin screen (98.7% category agreement to reference method)
Global Division Siemens Healthcare Diagnostics Inc. 511 Benedict Avenue Tarrytown, NY 10591-5005 USA www.siemens.com/diagnostics
Versatility for your unique testing needs. Experience flexibility and choice through dynamic MicroScan menu options designed to streamline testing and help boost your efficiency. Manage changing formulary needs
with a broad antimicrobic menu and more than 95 MicroScan panel choices (available globally)
Select ID-only, AST-only, and ID/AST combination panels for workflow flexibility
Utilize a one-panel format for all Siemens microbiology instruments for simplified testing procedures and streamlined workflow
Perform and interpret tests manually or on MicroScan instrumentation
Aligns with most EUCAST guidelines
Stay ahead of emerging resistance the trusted way.
First-time accuracy The MicroScan system uses a growth-based, non-ID-dependent direct testing method, which allows for better detection of emerging resistance. The system does not rely on historical data: It provides a real-time advantage for accuracy and uses direct MIC* technology to detect emerging and low-level resistance. This means fewer confirmatory tests are needed, providing you with accurate results the first time. This functionality aligns with most CLSI guidelines to improve detection of resistance mechanisms without additional confirmation tests.
*Minimum inhibitory concentration
Panel Name Pos Staph Combo 30Pos Strep Combo 36
Pos Combo 35
Pos Combo 37
Pos Combo 38
Pos Combo 42
Pos BP Combo 32
Pos BP Combo 33 Pos MIC 31 Pos MIC 32 Pos MIC 33
SMN 10460351 10479096 10479093 10479102 10479103 10713829 10479094 10479106 10479099 10479107 10713828
Legacy Catalog Number B1016 135 B1016 154 B1016 151 B1016 160 B1016 161 B1016 174 B1016 152 B1016 164 B1016 157 B1016 165 B1016 173
Languages FR E, FR, NO E, FR, GR, NO, PL E, ES, GR, PL, PT E, ES, GR, PL, PT DE, E, ES, FR, GR, IT, PL, PT, TR DE, E, GR, IT,
NO, PLDE, E, FR, GR,
IT, NO, PL E, FR, NODE, E, FR, GR,
IT, NO, PLDE, E, ES, FR, GR,
IT, PL, PT, TR Abbr. Antimicrobic Agent g/mL g/mL g/mL g/mL g/mL g/mL g/mL g/mL g/mL g/mL g/mL Abbr.
Ak Amikacin 8 16 8 32 8 32 AkAug Amoxicillin/K Clavulanate 4/2 8/4 4/2 8/4 4/2 8/4 2/1 8/4 0.5/0.25 8/4 4/2 8/4 AugAm Ampicillin 0.12 8 1 8 1 8 0.25, 4 8 4 8 2 8 0.12 8 0.5 8 0.25, 4 8 AmAzi Azithromycin 1 2 1 2 1 2 AziCpe Cefepime 4 8 CpeCft Cefotaxime 0.5, 16 0.5, 16 1 2 Cft
CfxS Cefoxitin Screen 4 4 4 4 4 4 4 4 4 4 CfxSCpt Ceftaroline 0.5 1 0.5 1 CptCrm Cefuroxime 4 8 CrmCf Cephalothin 8 16 CfC Chloramphenicol 8 16 8 16 8 16 8 8 16 8 8 16 C
Cp Ciprofloxacin 0.5 2 0.5 2 0.5 2 1 2 1 2 0.5 1 0.5 1 1 2 CpCla Clarithromycin 1 2 ClaCd Clindamycin 0.25 2 0.25 2 0.25 2 0.25 2 0.25 2 0.25 0.5, 2 0.25 0.5, 2 0.25 2 0.25 0.5, 2 0.25 2 Cd
Dap Daptomycin 1 4 1 4 0.5 4 0.25 4 1 4 1, 4 1 4 1 0.5 4 1 4 DapEtp Ertapenem 0.5 1 EtpE Erythromycin 1 8 0.25 4 0.5 2 0.5 4 0.25 4 0.5 4 1 2 1 2 0.25 4 1 2 0.5 4 E
Fos Fosfomycin 32 32 64 32 64 32 64 32 32 32 32 32 64 FosFA Fusidic Acid 2, 16 2, 16 2, 16 2, 16 2 2 2 2 FAGm Gentamicin 1 4 1 4 1 4 1 2 1, 4 8 1 2 1 4 1 1 4 1 8 Gm
GmS Gentamicin Synergy Screen 500 500 500 500 500 500 500 500 500 GmSImp Imipenem 1 2 2 8 1 2 2 8 4 8 ImpICd Inducible Clindamycin Test 4/0.5 4/0.5 4/0.5 4/0.5 4/0.5 4/0.5 4/0.5 4/0.5 4/0.5 4/0.5 ICdK Kanamycin 2 16 4 16 K
KS Kanamycin Synergy Screen 1,000 1,000 KSLvx Levofloxacin 1 4 1 4 1 4 1 4 1 4 1 4 1 2 0.5 4 1 2 1 4 LvxLin Lincomycin 1 8 1 8 1 8 LinLzd Linezolid 1 4 0.5 4 1 4 1 4 1 4 2 4 2 4 2 4 0.5 4 0.5 4 1 4 LzdMer Meropenem 28 MerMin Minocycline 1 1 8 MinMxf Moxifloxacin 0.5 2 0.5 1 0.5 1 0.5 1 0.5 2 0.5 1 0.5 1 MxfMup Mupirocin 4, 256 4 8, 256 4 8, 256 256 4 8, 256 4 8 4 8, 256 256 MupNt Netilmicin 2 4 NtFd Nitrofurantoin 32 64 64 64 32 64 32 64 32 64 32 64 64 64 64 32 64 Fd
Nxn Norfloxacin 4 8 4 8 NxnOfl Ofloxacin 1 4 0.5 4 OflOx Oxacillin 0.25 2 0.25 2 0.25 2 0.25 2 0.25 2 0.25, 1 2 0.25 2 0.25 2 0.25 2 0.25 2 OxP Penicillin 0.25 1, 16 0.03,0.12 0.25,2 0.03,0.12 0.25,2 0.03,0.12 0.25 0.03,0.12 0.25,2,8 0.12 0.25 0.03 0.12, 8 0.12 0.25, 2 0.03 0.25, 2 0.03 0.25, 2 0.12 0.25, 8 P
Prs Pristinamycin 0.5 2 1 2 1 2 1 2 1 2 PrsRif Rifampin 0.5 1, 4, 16 0.5, 4, 16 1 2 0.5 2 1 2 1 2 0.5, 4 16 0.5 2 0.5 2 RifStS Streptomycin Synergy Screen 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 StSSyn Synercid 0.25 2 1 4 1 4 1 4 1 4 1 4 1 4 0.5 4 1 4 1 4 SynTei Teicoplanin 1 8 1 8 2 8 1 8 1 8 2 16 1 8 2 8 1 8 1 8 1 16 TeiTe Tetracycline 4 8 1 8 1 2 1 2 1 8 1 8 1 2 1 2 1 8 1 2 1 8 TeTo Tobramycin 1 2 1 2 1, 4 8 1 1 4 1 8 ToT/S Trimethoprim/Sulfamethoxazole 2/38, 8/152 1/19 2/38 1/19 4/76 1/19 4/76 2/38 4/76 2/38 4/76 1/19 4/76 1/19 4/76 1/19 4/76 2/38 4/76 T/SVa Vancomycin 1 8 1 8 0.5 8 0.5 8 0.25 8 1 16 0.5 8 0.5 8 1 8 0.25 8 0.25 16 Va
Total Antimicrobics/Panel 23 22 26 23 21 26 30 29 34 35 34
Panel DefinitionsPos Staph Combo: Provides gram-positive identification and susceptibility results on one panel. Drug selection provides staphylococci coverage, as well as urine and systemic reporting. Pos Strep Combo: Provides gram-positive identification and susceptibility results on one panel. Drug selection provides streptococci coverage, as well as urine and systemic reporting. Pos Combo: Provides gram-positive identification and susceptibility results on one panel. Drug selection provides both staphylococci and enterococci coverage, as well as urine and systemic reporting.Pos BP Combo: Provides gram- positive identification and susceptibility results on one panel. Drug selection provides both staphylococci and enterococci coverage, as well as urine and systemic reporting. Panel contains shorter dilutions around the breakpoints, allowing for a broader drug menu.Pos MIC: Provide gram-positive susceptibility results only and longer dilution schemes for better detection of emerging resistance. Drug selection provides both staphylococci and enterococci coverage, as well as urine and systemic reporting.
Not for sale in the U.S., China, or Japan
Legend: DE German E English ES Spanish FR French GR Greek IT Italian NO Norwegian PL Polish PT Portuguese TR Turkish